Stem Cell Therapy for Knees: Cost, Success Rates, and How It Compares to Surgery
- Stem cell injections for knees range from $3,000 to $25,000+ depending on cell type, with no insurance coverage for most patients.
- Success rates depend heavily on arthritis severity: KL Grade I-II patients see 60-80% symptom improvement; Grade III drops to 40-60%; Grade IV results are limited.
- BMAC and adipose-derived SVF are the most clinically studied options; amniotic and umbilical cord products marketed at clinics rarely contain live cells.
- Stem cell therapy does not reverse severe structural damage but can delay or avoid surgery in well-selected candidates.
- Red flags include guarantees of cartilage regeneration, vague cell sourcing, and pressure to buy multiple sessions upfront.
Knee pain that does not respond to physical therapy or anti-inflammatory medication puts a lot of people in a difficult position. Surgery feels drastic. Doing nothing feels like giving up. Stem cell therapy sits in between, promising regeneration rather than replacement. But the marketing has outrun the science in several ways, and knowing the difference matters before you spend thousands of dollars.
This guide covers what the evidence actually shows, what each type of stem cell product costs, how success rates break down by disease severity, and when this treatment is and is not a reasonable choice. For a broader look at regenerative medicine options, see our Stem Cell Therapy Guide and Osteoarthritis Treatment Guide.
Types of Stem Cell Products Used for Knees
Not all products marketed as “stem cell therapy” contain the same thing, and the differences matter clinically and financially.
Bone Marrow Aspirate Concentrate (BMAC)
BMAC is drawn from your iliac crest (hip bone), spun down in a centrifuge, and injected into the knee during the same visit. The concentrate contains mesenchymal stem cells (MSCs), platelets, and growth factors. Cell counts vary considerably by patient age and health status. This is the most studied autologous (your own cells) approach and is performed in a single-day outpatient procedure.
Cost range: $3,000 to $8,000 per treatment. The harvest procedure adds time and a second puncture site, which is why pricing sits above PRP but below culture-expanded options.
Adipose-Derived Stromal Vascular Fraction (SVF)
Fat tissue harvested via mini-liposuction is enzymatically or mechanically processed to isolate the SVF, which contains MSCs, pericytes, endothelial progenitor cells, and growth factors. Adipose tissue yields higher raw MSC numbers than bone marrow in most patients. Same-day procedures are possible with mechanical processing; enzymatic processing technically requires FDA oversight as a more-than-minimally-manipulated cell product.
Cost range: $4,000 to $10,000. The mini-liposuction step adds procedural complexity and cost compared to BMAC.
Culture-Expanded MSCs
Some clinics (primarily outside the U.S.) take bone marrow or adipose cells, culture them in a lab for several weeks to multiply the cell count, then cryopreserve and ship them for injection. This produces far higher cell doses (50-200 million cells vs. a few thousand to tens of thousands in BMAC). In the United States, culture-expanded MSCs require FDA IND approval for clinical use, which is why most offering clinics operate in Mexico, Panama, or the Cayman Islands.
Cost range: $10,000 to $25,000+, often bundled with travel and accommodation.
Amniotic and Umbilical Cord Products
These allogeneic products are derived from placental tissue, amniotic membrane, or Wharton’s jelly in umbilical cords. They are widely marketed as containing live stem cells. Independent laboratory testing funded by the FDA and academic centers has repeatedly found that commercial amniotic and umbilical cord products contain few to no viable cells after processing and cryopreservation. What remains are growth factors, cytokines, and extracellular matrix proteins, which may have value but are not “stem cells” in any meaningful functional sense.
Cost range: $2,500 to $6,000. The scientific basis for the premium over PRP is questionable based on current evidence.
What the Evidence Shows
Three key clinical studies define what we reasonably know about stem cell injections for knee osteoarthritis.
Shapiro et al., 2017 (STEM CELLS Translational Medicine, N=25 RCT): This was one of the first randomized controlled trials comparing intra-articular BMAC to saline placebo in knee OA. Both groups improved at 12 months, with no statistically significant difference between BMAC and placebo on primary pain outcomes. The study highlighted the substantial placebo effect in knee injection trials and the need for larger, controlled studies.
Pers et al., 2016 (STEM CELLS Translational Medicine, N=18): A dose-escalation study of adipose-derived SVF in knee OA. All three dose groups showed significant improvement in pain and function scores at 6 months, with the lowest complication rates at the mid-dose. No serious adverse events were reported. Limitations include the small sample size and absence of a control group.
Vega et al., 2015 (Transplantation, N=30 RCT): Compared allogeneic bone marrow-derived MSCs to hyaluronic acid in knee OA. The MSC group showed significantly greater improvements in pain, function, and MRI-measured cartilage quality at 12 months. This is one of the stronger early RCTs, though still limited by sample size.
The honest summary: the evidence base is encouraging but not conclusive. Most studies are small, short-term, and lack rigorous placebo controls. Larger phase III trials are ongoing. Stem cell therapy for knees is not experimental in the sense that it has no basis, but it is not proven in the sense that major medical societies recommend it as standard of care.
Success Rates by Kellgren-Lawrence Grade
Kellgren-Lawrence (KL) grading is the standard radiographic scale for osteoarthritis severity, from Grade I (minor) to Grade IV (severe bone-on-bone). Where you fall on this scale is probably the single most predictive factor for whether stem cell therapy will help you.
| KL Grade | Description | Expected Improvement Rate | Appropriate Candidate? |
|---|---|---|---|
| Grade I | Possible osteophytes, no joint space narrowing | 60-80% symptom improvement | Yes, strong candidate |
| Grade II | Definite osteophytes, possible narrowing | 60-80% symptom improvement | Yes, good candidate |
| Grade III | Multiple osteophytes, definite narrowing, some sclerosis | 40-60% symptom improvement | Reasonable candidate with realistic expectations |
| Grade IV | Large osteophytes, severe narrowing, bone-on-bone | Limited; 20-30% at best | Poor candidate; surgery often more appropriate |
“Improvement” here refers to clinically meaningful reductions in KOOS (Knee Injury and Osteoarthritis Outcome Score) pain and function subscales, typically defined as a 10-point or greater improvement. It does not mean cartilage regrowth, which is rarely demonstrated on follow-up MRI in most clinical studies.
What Does “Success” Actually Mean?
Clinics advertising “80% success rates” are usually measuring patient-reported satisfaction or pain scores at 3-6 months, not MRI-confirmed cartilage regeneration. These are two very different things.
The most commonly used outcome measures in stem cell knee trials are KOOS subscales (pain, symptoms, activities of daily living, sport/recreation, quality of life) and VAS pain scores. A meaningful response is generally defined as a 30-50% reduction in pain scores maintained at 12 months. A minority of studies report MRI findings, and among those, improvements in cartilage thickness or T2 mapping are modest and not universal.
Duration of benefit is another open question. Studies following patients past 24 months are few. The working clinical assumption is that benefits may last 1-3 years in good responders, after which retreatment may be considered. No good predictors of durability exist yet.
Cost Breakdown and What You Are Paying For
Stem cell knee injections are not covered by any major U.S. insurance carrier for osteoarthritis or sports injuries. The full cost comes out of pocket. Here is what the pricing typically includes.
| Product Type | Cost Range | Cell Source | Same-Day Procedure | FDA Status |
|---|---|---|---|---|
| BMAC | $3,000-$8,000 | Patient (autologous) | Yes | Minimal manipulation (compliant) |
| Adipose SVF (mechanical) | $4,000-$10,000 | Patient (autologous) | Yes | Minimal manipulation (compliant) |
| Adipose SVF (enzymatic) | $6,000-$12,000 | Patient (autologous) | No | Requires IND under FDA rules |
| Amniotic/Umbilical products | $2,500-$6,000 | Donor (allogeneic) | Yes | Regulated as biologics; enforcement varies |
| Culture-Expanded MSCs | $10,000-$25,000+ | Patient or donor | No (travel required) | Requires IND in U.S.; often done abroad |
Cost components typically include the consultation, imaging (ultrasound or fluoroscopy for injection guidance), the cell harvest or product acquisition, the injection itself, and sometimes a follow-up visit. Integration therapy, physical therapy protocols, or PRP add-ons may add $500-$2,000 more.
Stem Cell Therapy vs. Knee Replacement Surgery
Total knee replacement (TKR) is one of the most performed elective surgeries in the U.S., with roughly 700,000 procedures annually. It is effective for Grade IV disease, with 90% of patients reporting significant pain relief and functional improvement at 10 years. But it comes with real trade-offs.
| Factor | Stem Cell Injection | Total Knee Replacement |
|---|---|---|
| Cost (out-of-pocket) | $3,000-$25,000 | $30,000-$50,000 (with insurance); $35,000-$70,000 without |
| Recovery time | 1-3 days downtime; full activity in 2-4 weeks | 6-12 weeks limited; full recovery 3-6 months |
| Efficacy in Grade IV OA | Limited (20-30%) | High (85-90%) |
| Efficacy in Grade I-II OA | Good (60-80%) | Not indicated (overkill) |
| Reversibility | Reversible; can still have surgery later | Permanent structural change |
| Implant lifespan | N/A | 15-20 years; revision needed eventually |
| Insurance coverage | None | Yes, under Medicare/most plans |
The key insight is that stem cell therapy and knee replacement are not competing for the same patients. Grade I-III patients are not typically candidates for TKR, so stem cell therapy fills a gap where surgery is not yet indicated but pain is significant. Grade IV patients with bone-on-bone arthritis are unlikely to get adequate relief from stem cell injections.
Who Is a Good Candidate?
Good candidates share several characteristics: KL Grade I-III osteoarthritis confirmed by X-ray or MRI; persistent pain and functional limitation despite 3-6 months of physical therapy and anti-inflammatory treatment; BMI below 35 (higher BMI is associated with worse outcomes); no active infection or inflammatory arthritis (rheumatoid, psoriatic); and realistic expectations about outcomes.
Age matters less than joint condition. A 65-year-old with Grade II OA may respond better than a 45-year-old with Grade IV disease. Athletes with focal cartilage defects rather than diffuse OA may also be reasonable candidates, though this is a different clinical indication with its own evidence base.
Who Is Not a Good Candidate?
Patients with Grade IV bone-on-bone arthritis and significant varus or valgus deformity are unlikely to benefit meaningfully. Active cancer, blood disorders, or immunosuppressive therapy are contraindications. Patients with active joint infection, inflammatory arthritis flares, or clotting disorders should not proceed. Anyone expecting guaranteed cartilage regeneration should recalibrate expectations before spending this kind of money.
Red Flags in Stem Cell Marketing
Be skeptical of any clinic that guarantees cartilage regrowth based on their injection. Be skeptical of vague descriptions like “millions of stem cells” without specifying cell type, viability, or sourcing. Be skeptical of pressure to purchase package deals of 3-5 sessions without a single-treatment trial first. Be skeptical of before-and-after MRI images shown without objective radiologist reports.
Legitimate regenerative medicine clinics will discuss failure rates openly, recommend imaging-guided injection, provide written informed consent covering all risks and the experimental status of the treatment, and not pressure you into a decision at the first consultation.
The Bottom Line
Stem cell injections for knee osteoarthritis occupy a legitimate but imprecisely defined clinical space. The biology is sound, early clinical results are promising for the right patients, and for Grade I-III disease the risk-to-benefit profile is reasonable. The cost is high, the evidence is not yet at the level that justifies broad adoption, and the marketing around certain products (particularly amniotic and umbilical cord products) is significantly ahead of the science.
If you have moderate knee OA that has not responded to conservative care, and you have realistic expectations and budget for the cost, BMAC or adipose SVF from a reputable clinic is a defensible choice. If you have severe Grade IV disease and are hoping to avoid a knee replacement, this is probably not the solution. Talk to an orthopedic surgeon and a regenerative medicine specialist together before deciding.
Related Reading
- Arthritis Guide: Rheumatoid Arthritis and Osteoarthritis
- Osteoarthritis: What It Is, Why It Progresses, and How Regenerative Medicine Is Changing Treatment
- Stem Cell Therapy: Types, Evidence, Cost, Risks, and What You Need to Know
Frequently Asked Questions
How much does stem cell therapy for the knee cost?
The page puts the range at $3,000 to $25,000 or more, depending on the cell type and how it is processed. Bone marrow concentrate (BMAC) runs $3,000 to $8,000, adipose SVF $4,000 to $12,000, culture-expanded MSCs $10,000 to $25,000 and up, and amniotic or umbilical products $2,500 to $6,000. Cost is driven by product type, cell sourcing, procedural complexity, and whether cells are culture-expanded, with same-day procedures costing less than those needing lab expansion and travel.
Does stem cell therapy for the knee actually work?
The evidence is described as encouraging but not conclusive, drawn from small, short-term studies. Results are mixed: Shapiro et al. (2017) found no statistically significant difference between BMAC and placebo, while Vega et al. (2015) found the MSC group had significantly greater improvements in pain, function, and MRI-measured cartilage quality. Reported improvement means a reduction in pain scores, not cartilage regrowth.
How do success rates depend on how severe my arthritis is?
Outcomes track closely with Kellgren-Lawrence grade. The page cites roughly 60 to 80 percent symptom improvement for Grade I-II, 40 to 60 percent for Grade III, and limited results of 20 to 30 percent at best for Grade IV. For Grade I-III disease it calls the risk-to-benefit profile reasonable, but for severe Grade IV bone-on-bone arthritis it says this is probably not the solution.
Is it covered by insurance?
No. The page states that stem cell knee injections are not covered by any major U.S. insurance carrier for osteoarthritis or sports injuries, so patients pay out of pocket.
How long do the results last?
The page is candid that timing and duration are open questions. Studies measured outcomes at 6 to 12 months, and it describes the working clinical assumption that benefits may last 1 to 3 years rather than a settled figure.
Am I a good candidate for this treatment?
Good candidates are described as having KL Grade I-III osteoarthritis confirmed by X-ray or MRI, persistent pain despite 3 to 6 months of physical therapy and anti-inflammatory treatment, and a BMI below 35. Poor candidates include those with Grade IV bone-on-bone arthritis and significant varus or valgus deformity, active infection, inflammatory arthritis, or those on immunosuppressive therapy.
